Compare · GLP-1 agonist
Amycretin vs Mazdutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Amycretin | Mazdutide | |
|---|---|---|
| Evidence | Preliminary human | Preliminary human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational single-molecule GLP-1 and amylin receptor agonist from Novo Nordisk with eye-catching early-phase weight-loss data, but no completed Phase 3 trials and no approval anywhere. | A GLP-1/glucagon dual agonist approved in China for weight loss and diabetes, with genuine RCT evidence that is still sponsor-funded and single-country. |
| Full profile → | Full profile → |
Amycretin
Amycretin is an investigational drug from Novo Nordisk that has generated some striking early-phase weight-loss numbers, which is exactly why it shows up on peptide forums and gray-market menus. It is a single-molecule ("unimolecular") peptide that activates two receptors at once — the GLP-1…
Mazdutide
Mazdutide is an injectable drug for weight loss and type 2 diabetes that activates two metabolic hormone receptors at once. Unlike most of the attention-grabbing GLP-1 compounds, it is not stuck at the press-release stage: it has a published Phase 3 trial in a major journal and is actually approved…